EMA approves biosimilar interchangeability in EU
European Pharmaceutical Review
SEPTEMBER 20, 2022
This interchangeability refers to the fact that a reference medicine can be substituted by a biosimilar, without risk, side effects or outcomes different to the original drug. Clinically, it is common practice for doctors to rotate patients between different biologics. New regulatory guidance could lead to UK biosimilar boom.
Let's personalize your content